The Spectrum of Serious Infections Among Patients Receiving Immune Checkpoint Blockade for the Treatment of Melanoma

Prevention and Treatment of Cancer-Related Infections

(2017) Lindsey Robert Baden et al.   Journal of the National Comprehensive Cancer Network

Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders

(2016) Douglas B. Johnson et al.   JAMA Oncology

Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center

(2015) Troy Z. Horvat et al.   JOURNAL OF CLINICAL ONCOLOGY

Autoimmune Colitis and Subsequent CMV-induced Hepatitis After Treatment With Ipilimumab

(2015) Ugur Uslu et al.   JOURNAL OF IMMUNOTHERAPY

Ipilimumab-induced colitis in patients with metastatic melanoma

(2015) Kara M. De Felice et al.   MELANOMA RESEARCH

Nivolumab in Previously Untreated Melanoma without BRAF Mutation

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma

(2015) Michael A. Postow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

(2015) Julie Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

(2015) Stephen M. Ansell et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

(2015) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab versus Ipilimumab in Advanced Melanoma

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immunosuppression for ipilimumab-related toxicity can causepneumocystispneumonia but spare antitumor immune control

(2015) Edurne Arriola et al.   OncoImmunology

PDL-1 Blockade Impedes T Cell Expansion and Protective Immunity Primed by Attenuated Listeria monocytogenes

(2014) J. H. Rowe et al.   JOURNAL OF IMMUNOLOGY

Opportunistic infections in patients treated with immunotherapy for cancer

(2014) Chrisann Kyi et al.   Journal for ImmunoTherapy of Cancer

Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab

(2012) Jeffrey S. Weber et al.   JOURNAL OF CLINICAL ONCOLOGY

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Programmed death-1 (PD-1)-deficient mice are extraordinarily sensitive to tuberculosis

(2010) E. Lazar-Molnar et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group

(2008) Ben De Pauw et al.   CLINICAL INFECTIOUS DISEASES

Blockade of endogenous B7-H1 suppresses antibacterial protection after primary Listeria monocytogenes infection

(2007) Su-Kil Seo et al.   IMMUNOLOGY